Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]) has promoted Kevin Fitzgerald, its head of research, to senior vice president and chief scientific officer. Fitzgerald joined Cambridge, MA-based Alnylam in 2005. In other moves, Alnylam appointed Kelley Boucher senior vice president and chief human resources officer. Boucher was most recently vice president and head of global human resources for Abiomed. Alnylam develops drugs that employ a gene-silencing approach called RNA interference.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
